What is the global market size of Gastroenterology Market?

Gastroenterology Market size was valued at USD 32.58 billion in 2022 and is poised to grow from USD 34.53 billion in 2023 to USD 55.04 billion by 2031, growing at a CAGR of 6% in the forecast period (2024-2031).

Who are the key vendors in the Global Gastroenterology Market?

The market for gastrointestinal medicines is moderately fragmented. To increase their market share, the market players have widely used competition sustainability methods such as new product development and regional and distribution channel expansion. Furthermore, a greater emphasis on supply chain management and operational improvement has made it easier for major companies to keep a competitive edge. 'AbbVie Inc.', 'Allergan plc', 'AstraZeneca plc', 'Boehringer Ingelheim International GmbH', 'Eisai Co., Ltd.', 'GlaxoSmithKline plc', 'Johnson & Johnson', 'Novartis International AG', 'Pfizer Inc.', 'Procter & Gamble Co.', 'Salix Pharmaceuticals, Inc.', 'Sanofi S.A.', 'Shire plc', 'Takeda Pharmaceutical Company Limited', 'Valeant Pharmaceuticals International, Inc.', 'Amgen Inc.', 'Aptalis Pharma US, Inc.', 'Danone S.A.', 'Ferring Pharmaceuticals', 'Nestle Health Science'

Gastroenterology Market Size

SkyQuest Technology's Gastroenterology market size, share and forecast Report is based on the analysis of market data and Industry trends impacting the global Gastroenterology Market and the revenue of top companies operating in it. Market Size Data and Statistics are based on the comprehensive research by our Team of Analysts and Industry experts.

Gastroenterology Market Insights

Global Gastroenterology Market size was valued at USD 37.4 billion in 2023 and is poised to grow from USD 62.65 billion in 2024 to USD 62.65 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The market for gastroenterology is expanding primarily due to the rising prevalence of gastrointestinal diseases. Other significant reasons driving the growth of the gastroenterology market are the rising incidence of gastrointestinal disorders brought on by poor dietary practices, the expansion of clinical studies with reliable findings, rising healthcare costs, and the rise in the elderly population.

There is a large variety of new generation treatments that are available, including cellular therapy and inventive small compounds. Hospitalizations and surgical procedures for GI disorders are on the rise, and biopharmaceutical companies are investing more in R&D to create biologics and biosimilars. According to the National Clinical Trials (NCT) registry, there were around 6,443 ongoing clinical trials for gastrointestinal illnesses at various stages of development as of May 2021. Over the projection period, new chances for efficient medicines may be created by the successful findings of these investigations.

US Gastroenterology Market is poised to grow at a sustainable CAGR for the next forecast year.

Gastroenterology Market Report Snapshots

REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

The market for gastrointestinal medicines is moderately fragmented. To increase their market share, the market players have widely used competition sustainability methods such as new product development and regional and distribution channel expansion. Furthermore, a greater emphasis on supply chain management and operational improvement has made it easier for major companies to keep a competitive edge. 'AbbVie Inc. (USA) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'AstraZeneca plc (UK) ', 'Bayer AG (Germany) ', 'Pfizer Inc. (USA) ', 'Johnson & Johnson (USA) ', 'Novartis AG (Switzerland) ', 'Merck & Co., Inc. (USA) ', 'Sanofi S.A. (France) ', 'GlaxoSmithKline plc (UK) ', 'Boehringer Ingelheim International GmbH (Germany) ', 'Teva Pharmaceutical Industries Limited (Israel) ', 'Boston Scientific Corporation (USA) ', 'Medtronic plc (Ireland) ', 'Olympus Corporation (Japan) ', 'Fujifilm Corporation (Japan) ', 'Stryker Corporation (USA) ', 'Nestle Health Science (Switzerland) ', 'Danone S.A. (France) '

Rising incidence of gastrointestinal diseases: Globally, the prevalence of gastrointestinal conditions such gallstones, ulcerative colitis, fissure, hemorrhoids, irritable bowel syndrome (IBS), and gastroesophageal reflux disease (GERD) has dramatically grown. The main causes of the rising prevalence of chronic and acute gastrointestinal illnesses are poor diet, a sedentary lifestyle, stress, food sensitivity, and bacterial or viral infections. Numerous drugs, such as antacids, histamine H2-receptor antagonists, laxatives, proton pump inhibitors, and antibiotics, are increasingly in demand to treat various gastrointestinal disorders and prevent subsequent medical consequences related to the diseases. This is driving up the demand for different classes or types of pharmaceuticals to treat gastrointestinal ailments, which is driving up the growth of the global market for therapeutics for gastrointestinal diseases.

The demand for developing cutting-edge medicines is being driven by the increase in severe to moderate gastrointestinal disorders, such as ulcerative colitis, Crohn's disease, and other gastrointestinal ailments. In order to expand their product pipeline, pharmaceutical and biotechnology businesses are concentrating on R&D to find and create novel medications for the treatment of gastrointestinal illnesses. The global market for gastrointestinal illnesses therapeutics is anticipated to see growth prospects during the forecast period as a result of firms' increasing focus on the development of revolutionary innovative therapies for effectively treating gastrointestinal ailments. During the forecast period, the growing development of gastrointestinal illness medications by regional and international vendors is anticipated to significantly contribute to the growth of the worldwide gastrointestinal disorders therapeutics market.

Based on the region, the North American region currently dominates the global gastroenterology market. The market in North America had the biggest share in 2021 and is anticipated to hold that position during the projected period. Technological advancements, an unprecedented change in lifestyle leading to a higher incidence of gastrointestinal diseases, an increase in the number of geriatric and obese people, and rising research and development activities with the presence of key market players are some of the factors that are fueling the market growth in the North American region. Additionally, the government's measures to prevent and treat gastrointestinal disorders are anticipated to propel the market. For instance, UNICEF and WHO's Integrated Global Action Plan for Diarrhea aims to reduce the number of child deaths that can be prevented due to diarrhea by providing interventions and services to increase awareness and offer access to treatment and preventative measures.

Gastroenterology Market Size

Gastroenterology Market Insights

Gastroenterology Market Report Snapshots

FAQs

What is the global market size of Gastroenterology Market?

Who are the key vendors in the Gastroenterology Market?

What is the key driver of Gastroenterology Market?

What is the key market trend for Gastroenterology Market?

Which region accounted for the largest share in Gastroenterology Market?

Request Free Customization